 | • レポートコード：D0GIR-00260 • 出版社/出版日：GlobalInfoResearch / 2020年9月18日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、105ページ • 納品方法：Eメール • 産業分類：医療、製薬、バイオ |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、急性肝性ポルフィリン症治療薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。急性肝性ポルフィリン症治療薬の種類別市場規模（350mg、313mg）、用途別市場規模（病院薬局、小売薬局、オンライン薬局、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Alnylam Pharmaceuticals、Recordati Rare Diseases ・地域別グローバル市場分析 2015年-2020年 ・急性肝性ポルフィリン症治療薬の北米市場（アメリカ、カナダ、メキシコ） ・急性肝性ポルフィリン症治療薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・急性肝性ポルフィリン症治療薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・急性肝性ポルフィリン症治療薬の南米市場（ブラジル、アルゼンチン） ・急性肝性ポルフィリン症治療薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：350mg、313mg ・用途別分析：病院薬局、小売薬局、オンライン薬局、その他 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論 |
Market Overview
The Acute Hepatic Porphyria Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The global Acute Hepatic Porphyria Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx%% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
Market segmentation
Acute Hepatic Porphyria Drug market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Acute Hepatic Porphyria Drug market has been segmented into:
350 Mg
313 Mg
By Application, Acute Hepatic Porphyria Drug has been segmented into:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Acute Hepatic Porphyria Drug market presented in the report. This section sheds light on the sales growth of different regional and country-level Acute Hepatic Porphyria Drug markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Acute Hepatic Porphyria Drug market.
The report offers in-depth assessment of the growth and other aspects of the Acute Hepatic Porphyria Drug market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Acute Hepatic Porphyria Drug Market Share Analysis
Acute Hepatic Porphyria Drug competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Acute Hepatic Porphyria Drug sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Acute Hepatic Porphyria Drug sales, revenue and market share for each player covered in this report.
The major players covered in Acute Hepatic Porphyria Drug are:
Alnylam Pharmaceuticals
Recordati Rare Diseases
Among other players domestic and global, Acute Hepatic Porphyria Drug market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
1 Acute Hepatic Porphyria Drug Market Overview
1.1 Product Overview and Scope of Acute Hepatic Porphyria Drug
1.2 Classification of Acute Hepatic Porphyria Drug by Type
1.2.1 Global Acute Hepatic Porphyria Drug Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Acute Hepatic Porphyria Drug Revenue Market Share by Type in 2019
1.2.3 350 Mg
1.2.4 313 Mg
1.3 Global Acute Hepatic Porphyria Drug Market by Application
1.3.1 Overview: Global Acute Hepatic Porphyria Drug Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.3.5 Others
1.4 Global Acute Hepatic Porphyria Drug Market by Regions
1.4.1 Global Acute Hepatic Porphyria Drug Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Acute Hepatic Porphyria Drug (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Acute Hepatic Porphyria Drug Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Acute Hepatic Porphyria Drug Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Acute Hepatic Porphyria Drug Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Acute Hepatic Porphyria Drug Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Acute Hepatic Porphyria Drug Status and Prospect (2015-2025)
2 Company Profiles
2.1 Alnylam Pharmaceuticals
2.1.1 Alnylam Pharmaceuticals Details
2.1.2 Alnylam Pharmaceuticals Major Business
2.1.3 Alnylam Pharmaceuticals SWOT Analysis
2.1.4 Alnylam Pharmaceuticals Product and Services
2.1.5 Alnylam Pharmaceuticals Acute Hepatic Porphyria Drug Revenue, Gross Margin and Market Share (2018-2019)
2.2 Recordati Rare Diseases
2.2.1 Recordati Rare Diseases Details
2.2.2 Recordati Rare Diseases Major Business
2.2.3 Recordati Rare Diseases SWOT Analysis
2.2.4 Recordati Rare Diseases Product and Services
2.2.5 Recordati Rare Diseases Acute Hepatic Porphyria Drug Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Acute Hepatic Porphyria Drug Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Acute Hepatic Porphyria Drug Players Market Share
3.2.2 Top 10 Acute Hepatic Porphyria Drug Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Acute Hepatic Porphyria Drug Revenue and Market Share by Regions
4.2 North America Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
4.3 Europe Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
4.5 South America Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
5 North America Acute Hepatic Porphyria Drug Revenue by Countries
5.1 North America Acute Hepatic Porphyria Drug Revenue by Countries (2015-2020)
5.2 USA Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
5.3 Canada Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
5.4 Mexico Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
6 Europe Acute Hepatic Porphyria Drug Revenue by Countries
6.1 Europe Acute Hepatic Porphyria Drug Revenue by Countries (2015-2020)
6.2 Germany Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
6.3 UK Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
6.4 France Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
6.5 Russia Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
6.6 Italy Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Acute Hepatic Porphyria Drug Revenue by Countries
7.1 Asia-Pacific Acute Hepatic Porphyria Drug Revenue by Countries (2015-2020)
7.2 China Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
7.3 Japan Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
7.4 Korea Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
7.5 India Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
8 South America Acute Hepatic Porphyria Drug Revenue by Countries
8.1 South America Acute Hepatic Porphyria Drug Revenue by Countries (2015-2020)
8.2 Brazil Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
8.3 Argentina Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Acute Hepatic Porphyria Drug by Countries
9.1 Middle East & Africa Acute Hepatic Porphyria Drug Revenue by Countries (2015-2020)
9.2 Saudi Arabia Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
9.3 UAE Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
9.4 Egypt Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
9.5 South Africa Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Acute Hepatic Porphyria Drug Revenue and Market Share by Type (2015-2020)
10.2 Global Acute Hepatic Porphyria Drug Market Forecast by Type (2019-2024)
10.3 350 Mg Revenue Growth Rate (2015-2025)
10.4 313 Mg Revenue Growth Rate (2015-2025)
11 Global Acute Hepatic Porphyria Drug Market Segment by Application
11.1 Global Acute Hepatic Porphyria Drug Revenue Market Share by Application (2015-2020)
11.2 Acute Hepatic Porphyria Drug Market Forecast by Application (2019-2024)
11.3 Hospital Pharmacy Revenue Growth (2015-2020)
11.4 Retail Pharmacy Revenue Growth (2015-2020)
11.5 Online Pharmacy Revenue Growth (2015-2020)
11.6 Others Revenue Growth (2015-2020)
12 Global Acute Hepatic Porphyria Drug Market Size Forecast (2021-2025)
12.1 Global Acute Hepatic Porphyria Drug Market Size Forecast (2021-2025)
12.2 Global Acute Hepatic Porphyria Drug Market Forecast by Regions (2021-2025)
12.3 North America Acute Hepatic Porphyria Drug Revenue Market Forecast (2021-2025)
12.4 Europe Acute Hepatic Porphyria Drug Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Acute Hepatic Porphyria Drug Revenue Market Forecast (2021-2025)
12.6 South America Acute Hepatic Porphyria Drug Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Acute Hepatic Porphyria Drug Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Acute Hepatic Porphyria Drug Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Acute Hepatic Porphyria Drug by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Acute Hepatic Porphyria Drug Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Acute Hepatic Porphyria Drug Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global Acute Hepatic Porphyria Drug Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. Alnylam Pharmaceuticals Corporate Information, Location and Competitors
Table 7. Alnylam Pharmaceuticals Acute Hepatic Porphyria Drug Major Business
Table 8. Alnylam Pharmaceuticals Acute Hepatic Porphyria Drug Total Revenue (USD Million) (2017-2018)
Table 9. Alnylam Pharmaceuticals SWOT Analysis
Table 10. Alnylam Pharmaceuticals Acute Hepatic Porphyria Drug Product and Solutions
Table 11. Alnylam Pharmaceuticals Acute Hepatic Porphyria Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. Recordati Rare Diseases Corporate Information, Location and Competitors
Table 13. Recordati Rare Diseases Acute Hepatic Porphyria Drug Major Business
Table 14. Recordati Rare Diseases Acute Hepatic Porphyria Drug Total Revenue (USD Million) (2018-2019)
Table 15. Recordati Rare Diseases SWOT Analysis
Table 16. Recordati Rare Diseases Acute Hepatic Porphyria Drug Product and Solutions
Table 17. Recordati Rare Diseases Acute Hepatic Porphyria Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. Global Acute Hepatic Porphyria Drug Revenue (Million USD) by Players (2015-2020)
Table 19. Global Acute Hepatic Porphyria Drug Revenue Share by Players (2015-2020)
Table 20. Global Acute Hepatic Porphyria Drug Revenue (Million USD) by Regions (2015-2020)
Table 21. Global Acute Hepatic Porphyria Drug Revenue Market Share by Regions (2015-2020)
Table 22. North America Acute Hepatic Porphyria Drug Revenue by Countries (2015-2020)
Table 23. North America Acute Hepatic Porphyria Drug Revenue Market Share by Countries (2015-2020)
Table 24. Europe Acute Hepatic Porphyria Drug Revenue (Million USD) by Countries (2015-2020)
Table 25. Asia-Pacific Acute Hepatic Porphyria Drug Revenue (Million USD) by Countries (2015-2020)
Table 26. South America Acute Hepatic Porphyria Drug Revenue by Countries (2015-2020)
Table 27. South America Acute Hepatic Porphyria Drug Revenue Market Share by Countries (2015-2020)
Table 28. Middle East and Africa Acute Hepatic Porphyria Drug Revenue (Million USD) by Countries (2015-2020)
Table 29. Middle East and Africa Acute Hepatic Porphyria Drug Revenue Market Share by Countries (2015-2020)
Table 30. Global Acute Hepatic Porphyria Drug Revenue (Million USD) by Type (2015-2020)
Table 31. Global Acute Hepatic Porphyria Drug Revenue Share by Type (2015-2020)
Table 32. Global Acute Hepatic Porphyria Drug Revenue Forecast by Type (2021-2025)
Table 33. Global Acute Hepatic Porphyria Drug Revenue by Application (2015-2020)
Table 34. Global Acute Hepatic Porphyria Drug Revenue Share by Application (2015-2020)
Table 35. Global Acute Hepatic Porphyria Drug Revenue Forecast by Application (2021-2025)
Table 36. Global Acute Hepatic Porphyria Drug Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Acute Hepatic Porphyria Drug Picture
Figure 2. Global Acute Hepatic Porphyria Drug Revenue Market Share by Type in 2019
Figure 3. 350 Mg Picture
Figure 4. 313 Mg Picture
Figure 5. Acute Hepatic Porphyria Drug Revenue Market Share by Application in 2019
Figure 6. Hospital Pharmacy Picture
Figure 7. Retail Pharmacy Picture
Figure 8. Online Pharmacy Picture
Figure 9. Others Picture
Figure 10. Global Acute Hepatic Porphyria Drug Revenue (USD Million) and Growth Rate (2015-2025)
Figure 11. North America Acute Hepatic Porphyria Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. Europe Acute Hepatic Porphyria Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Asia-Pacific Acute Hepatic Porphyria Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. South America Acute Hepatic Porphyria Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Middle East and Africa Acute Hepatic Porphyria Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Global Acute Hepatic Porphyria Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Global Acute Hepatic Porphyria Drug Revenue Share by Players in 2019
Figure 18. Global Top 5 Players Acute Hepatic Porphyria Drug Revenue Market Share in 2019
Figure 19. Global Top 10 Players Acute Hepatic Porphyria Drug Revenue Market Share in 2019
Figure 20. Key Players Market Share Trend
Figure 21. Global Acute Hepatic Porphyria Drug Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 22. Global Acute Hepatic Porphyria Drug Revenue Market Share by Regions (2015-2020)
Figure 23. Global Acute Hepatic Porphyria Drug Revenue Market Share by Regions in 2018
Figure 24. North America Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
Figure 25. Europe Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
Figure 26. Asia-Pacific Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
Figure 27. South America Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
Figure 28. Middle East and Africa Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
Figure 29. North America Acute Hepatic Porphyria Drug Revenue Market Share by Countries (2015-2020)
Figure 30. North America Acute Hepatic Porphyria Drug Revenue Market Share by Countries in 2019
Figure 31. USA Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
Figure 32. Canada Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
Figure 33. Mexico Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
Figure 34. Europe Acute Hepatic Porphyria Drug Revenue Market Share by Countries (2015-2020)
Figure 35. Europe Acute Hepatic Porphyria Drug Revenue Market Share by Countries in 2019
Figure 36. Germany Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
Figure 37. UK Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
Figure 38. France Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
Figure 39. Russia Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
Figure 40. Italy Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
Figure 41. Asia-Pacific Acute Hepatic Porphyria Drug Revenue Market Share by Countries (2015-2020)
Figure 42. Asia-Pacific Acute Hepatic Porphyria Drug Revenue Market Share by Countries in 2019
Figure 43. China Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
Figure 44. Japan Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
Figure 45. Korea Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
Figure 46. India Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
Figure 47. Southeast Asia Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
Figure 48. South America Acute Hepatic Porphyria Drug Revenue Market Share by Countries (2015-2020)
Figure 49. South America Acute Hepatic Porphyria Drug Revenue Market Share by Countries in 2019
Figure 50. Brazil Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
Figure 51. Argentina Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
Figure 52. Middle East and Africa Acute Hepatic Porphyria Drug Revenue Market Share by Countries (2015-2020)
Figure 53. Middle East and Africa Acute Hepatic Porphyria Drug Revenue Market Share by Countries in 2019
Figure 54. Saudi Arabia Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
Figure 55. UAE Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
Figure 56. Egypt Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
Figure 57. South Africa Acute Hepatic Porphyria Drug Revenue and Growth Rate (2015-2020)
Figure 58. Global Acute Hepatic Porphyria Drug Revenue Share by Type (2015-2020)
Figure 59. Global Acute Hepatic Porphyria Drug Revenue Share by Type in 2019
Figure 60. Global Acute Hepatic Porphyria Drug Market Share Forecast by Type (2021-2025)
Figure 61. Global 350 Mg Revenue Growth Rate (2015-2020)
Figure 62. Global 313 Mg Revenue Growth Rate (2015-2020)
Figure 63. Global Acute Hepatic Porphyria Drug Revenue Share by Application (2015-2020)
Figure 64. Global Acute Hepatic Porphyria Drug Revenue Share by Application in 2019
Figure 65. Global Acute Hepatic Porphyria Drug Market Share Forecast by Application (2021-2025)
Figure 66. Global Hospital Pharmacy Revenue Growth Rate (2015-2020)
Figure 67. Global Retail Pharmacy Revenue Growth Rate (2015-2020)
Figure 68. Global Online Pharmacy Revenue Growth Rate (2015-2020)
Figure 69. Global Others Revenue Growth Rate (2015-2020)
Figure 70. Global Acute Hepatic Porphyria Drug Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 71. Global Acute Hepatic Porphyria Drug Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 72. Global Acute Hepatic Porphyria Drug Revenue Market Share Forecast by Regions (2021-2025)
Figure 73. North America Acute Hepatic Porphyria Drug Revenue Market Forecast (2021-2025)
Figure 74. Europe Acute Hepatic Porphyria Drug Revenue Market Forecast (2021-2025)
Figure 75. Asia-Pacific Acute Hepatic Porphyria Drug Revenue Market Forecast (2021-2025)
Figure 76. South America Acute Hepatic Porphyria Drug Revenue Market Forecast (2021-2025)
Figure 77. Middle East and Africa Acute Hepatic Porphyria Drug Revenue Market Forecast (2021-2025)
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
肝抗ウイルス薬の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The Hepatic Antiviral Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization…- 急性虚血性脳卒中治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Acute Ischemic Stroke Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 2.0% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Acute Isc…
- 急性冠症候群（ACS）の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Acute Coronary Syndrome (ACS) market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.6% in the forecast period of 2020 to 2025 and will expected to reach USD 9240.7 million by 2025, from USD 8032.3 million in 2019. The Acute …
- 急性期治療用人工呼吸器の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The global Acute Care Ventilator market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Acute Care Ventilator m…
- 急性肺障害の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Acute Lung Injury market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 4.7% in the forecast period of 2020 to 2025 and will expected to reach USD 637.6 million by 2025, from USD 531.6 million in 2019. The Acute Lung Injury ma…